WP
CNTB

Woodline Partners’s Connect Biopharma Holdings CNTB Stock Holding History

Woodline Partners’s Portfolio CNTB Stock Details CNTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-43,871
Closed -$132K – 810
2022
Q1 		$132K Buy
+43,871
New +$185K ﹤0.01% 562

Other funds holding CNTB

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Woodline Partners's CNTB Position: Q2 2022 in Review

Woodline Partners sold out of Connect Biopharma Holdings (CNTB) in Q2 2022, closing a stake of 43,871 shares — an estimated $132K sold.

Woodline Partners first reported a position in CNTB in Q1 2022 and held it in 1 quarter. The position peaked at $132K in Q1 2022. 29 funds tracked by Wall St. Rank hold CNTB as of Q2 2022.

  • Woodline Partners reported no remaining Connect Biopharma Holdings position as of Q2 2022 after selling out during the quarter.
  • Woodline Partners sold 43,871 Connect Biopharma Holdings shares in Q2 2022, an estimated $132K.
  • Woodline Partners first reported a position in Connect Biopharma Holdings in Q1 2022 and held it in 1 quarter.
  • Woodline Partners's Connect Biopharma Holdings position peaked at $132K in Q1 2022.
  • 29 funds tracked by Wall St. Rank held Connect Biopharma Holdings as of Q2 2022.

Based on Woodline Partners's 13F filing for Q2 2022, filed 15 Aug 2022.